Is there really an age cutoff for stopping TRT?

What did @cbronsonmd actually say?

Short answer: he said there is no standard age cutoff for testosterone replacement therapy, joking that his patients stop "when they're in the ground." He also noted he has "very old patients on testosterone" and sees nothing wrong with that.

To be clear about what he did and did not claim: this was a brief, casual statement. He did not specify a patient population, cite safety data, or acknowledge any of the real clinical debates around TRT in older men. That brevity matters, because the topic deserves more nuance than a punchline can provide. He is not wrong that age alone is not a hard cutoff, but the way this landed left a lot unsaid.

Does the science back this up?

Partially. There is no established upper age limit for TRT in clinical guidelines, but that does not mean older men face no additional considerations. The evidence here is genuinely mixed, and anyone who tells you otherwise is simplifying.

The 2023 American Urological Association guidelines do not set an age ceiling for TRT in men with confirmed hypogonadism. That aligns with the general principle that symptomatic hypogonadism, defined as low testosterone with clinical symptoms, can occur at any age and is treatable at any age. Bhasin et al. (2018, New England Journal of Medicine) found benefits in older men across sexual function, bone density, and anemia in the Testosterone Trials, though cardiovascular signals remained a topic of ongoing scrutiny. A 2023 meta-analysis by Lincoff et al. in the New England Journal of Medicine found TRT was non-inferior to placebo for major cardiovascular events in men with hypogonadism, which partially addressed a long-standing safety concern for older patients. However, that study had specific enrollment criteria and should not be read as a blanket clearance.

What did they get wrong (or right)?

He got the core point right: age alone should not be the reason a man stops TRT if it is clinically appropriate and monitored. That is defensible. Where the video falls short is everything it omits.

Older men on TRT face legitimate monitoring considerations that deserve mention. Hematocrit elevation is more common with age, and polycythemia is a real risk, particularly with injectable formulations. Prostate monitoring remains standard practice, not because TRT is proven to cause prostate cancer, but because it can stimulate existing subclinical disease. Morgentaler et al. (2011, Journal of Urology) helped reframe the testosterone-prostate cancer narrative, but the field still recommends PSA surveillance in older men. Sleep apnea, cardiovascular history, and fluid retention all interact differently in aging physiology. Saying "there's nothing wrong with that" without any of this context is not technically false, but it is incomplete in a way that could mislead patients into thinking lifelong TRT is as uncomplicated for an 80-year-old as for a 45-year-old.

What should you actually know?

If you are an older man on TRT or considering it, the honest answer is: the decision should be made with a physician who is actively monitoring your labs, not based on a TikTok clip. There is reasonable evidence supporting continued TRT in older men with confirmed hypogonadism, but the monitoring burden increases with age, not decreases.

Key points worth knowing:

• Hematocrit should be checked regularly. Elevated red blood cell counts raise clotting risk, and this is more common in older patients and those using injectable testosterone.
• PSA monitoring is standard. TRT does not appear to cause prostate cancer in men without existing disease, but it can accelerate subclinical disease, so screening continues to matter.
• Bone density benefits are real. Multiple studies, including the Testosterone Trials (Snyder et al., 2017, JAMA Internal Medicine), showed improved bone mineral density in older hypogonadal men on TRT.
• The cardiovascular picture has improved but is not fully resolved. The Lincoff 2023 TRAVERSE trial was reassuring, but it followed a specific population for a defined period. Long-term data in very elderly men is still limited.
• Stopping TRT abruptly after long-term use can cause significant symptoms because endogenous production may be suppressed. Any decision to stop should be managed, not spontaneous.